Enliven Therapeutics (ELVN) Income from Non-Controlling Interests (2019 - 2026)
Enliven Therapeutics (ELVN) reported Income from Non-Controlling Interests of -$716000.0 for Q1 2026, down 908.45% on a YoY basis from $88564.5 in Q1 2025, and down 733.63% sequentially from $113000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Income from Non-Controlling Interests data on file, last reported at -$716000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 908.45% year-over-year to -$716000.0; the trailing twelve-month figure through Mar 2026 stood at -$366000.0 (down 1089.19% YoY), and the FY2025 full-year result was $279000.0, up 424.42% from the prior year.
- Income from Non-Controlling Interests slipped to -$716000.0 in Q1 2026, from $113000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $398000.0 in Q3 2025 to a low of -$716000.0 in Q1 2026.
- A 5-year average of -$32076.9 and a median of -$71000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests tumbled 1066.67% in 2022 and jumped 1158.33% in 2024, its largest moves.
- Tracing ELVN's Income from Non-Controlling Interests over 5 years: stood at -$35000.0 in 2022, then jumped by 922.86% to $288000.0 in 2023, then tumbled by 164.93% to -$187000.0 in 2024, then surged by 160.43% to $113000.0 in 2025, then plunged by 733.63% to -$716000.0 in 2026.
- Business Quant data shows ELVN's Income from Non-Controlling Interests at -$716000.0 in Q1 2026, $113000.0 in Q4 2025, and $398000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - | -716,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -716,000.00 |
| Dec 31, 2025 | 113,000.00 |
| Sep 30, 2025 | 398,000.00 |
| Jun 30, 2025 | -161,000.00 |
| Mar 31, 2025 | -71,000.00 |
| Dec 31, 2024 | -187,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | -86,000.00 |
| Mar 31, 2024 | -194,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | -36,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Dec 31, 2021 | -14,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -20,000.00 |
| Sep 30, 2020 | -24,000.00 |
| Jun 30, 2020 | 64,000.00 |